Abbvie earnings were $4.3B for the trailing 12 months ending Dec 31, 2024, with -12.1% growth year over year. The latest ABBV earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$22.0M, down 101.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABBV reported annual earnings of $4.3B, with -12% growth.
ABBV past earnings growth
How has ABBV's earnings growth performed historically?
On ABBV's earnings call on Invalid Date, Abbvie (NYSE: ABBV) reported Q4 2024 earnings per share (EPS) of -$0.01, up 102.17% year over year. Total ABBV earnings for the quarter were -$22.00 million. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.46.
As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $4.28 billion, a 12.03% decrease year over year.
What was ABBV's earnings growth in the past year?
As of Abbvie's earnings date in Invalid Date, Abbvie's earnings has grown -12.09% year over year. This is 379.68 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 367.59%. ABBV earnings in the past year totalled $4.28 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.